Overview
Tafero EM Tablets combine Emtricitabine (200 mg) and Tenofovir Alafenamide (25 mg), two potent nucleoside reverse transcriptase inhibitors (NRTIs) used for the treatment and prevention of HIV-1 infection. This formulation is known for its improved safety profile, particularly in terms of kidney and bone health, compared to earlier tenofovir-based treatments. Tafero EM is taken once daily and is suitable for use as part of combination antiretroviral therapy or for pre-exposure prophylaxis (PrEP) in high-risk individuals.





